Related Experiment Video
Updated: Dec 8, 2025
07:42
A Data-Driven Approach to Quantifying Immune States in Sepsis
Published on: February 7, 2025
408
Association between serum sFasL concentrations and sepsis mortality
Leonardo Lorente1, María M Martín2, Raquel Ortiz-López3
1Intensive Care Unit, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain.
Infectious Diseases (London, England)
|September 18, 2020
Summary
Higher blood soluble Fas Ligand (sFasL) levels are associated with increased mortality in sepsis patients, even after accounting for disease severity. This finding highlights sFasL as a potential predictor of sepsis outcomes.
Area of Science:
- Immunology
- Critical Care Medicine
- Molecular Biology
Background:
- Limited data exists on soluble Fas Ligand (sFasL) in sepsis.
- Previous studies suggested higher sFasL in non-survivors but lacked statistical power to control for sepsis severity.
Purpose of the Study:
- To investigate the association between blood sFasL concentrations and mortality in septic patients.
- To determine if sFasL can predict mortality independently of sepsis severity.
Main Methods:
- Observational, prospective study in three Spanish ICUs.
- Serum sFasL levels measured at sepsis diagnosis in 236 patients.
- Statistical analysis included logistic regression and Kaplan-Meier survival analysis.
Main Results:
- Non-survivors (n=85) had significantly higher serum sFasL levels than survivors (n=151).
- sFasL concentration was independently associated with mortality (OR=1.007, p<.001) after adjusting for clinical factors.
- sFasL demonstrated predictive value for mortality (AUC=62%, p=.003) and higher levels (>109 pg/mL) correlated with increased mortality risk (HR=3.6, p<.001).
Conclusions:
- Serum sFasL concentrations are significantly associated with mortality in septic patients, independent of sepsis severity.
- sFasL levels are elevated in non-survivors compared to survivors.
- Blood sFasL concentrations show potential as a predictive biomarker for sepsis mortality.
